Ionis Pharmaceuticals Inc
NASDAQ:IONS

Watchlist Manager
Ionis Pharmaceuticals Inc Logo
Ionis Pharmaceuticals Inc
NASDAQ:IONS
Watchlist
Price: 34.29 USD 1.03% Market Closed
Market Cap: 5.4B USD
Have any thoughts about
Ionis Pharmaceuticals Inc?
Write Note

Wall Street
Price Targets

IONS Price Targets Summary
Ionis Pharmaceuticals Inc

Wall Street analysts forecast IONS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IONS is 61.92 USD with a low forecast of 37.37 USD and a high forecast of 80.85 USD.

Lowest
Price Target
37.37 USD
9% Upside
Average
Price Target
61.92 USD
81% Upside
Highest
Price Target
80.85 USD
136% Upside

IONS Last Price Targets
Ionis Pharmaceuticals Inc

The latest public price target was made on Oct 9, 2024 by Debjit Chattopadhyay from Guggenheim , who expects IONS stock to rise by 90% over the next 12 months. You can read more about this price target by viewing the article on TheFly.

Analyst Price Target Date Article
Debjit Chattopadhyay
Guggenheim
65 USD
Upside 90%
1 month ago
Oct 9, 2024
Ionis Pharmaceuticals price target lowered to $65 from $70 at Guggenheim
TheFly
Kostas Biliouris
BMO Capital
60 USD
Upside 75%
3 months ago
Aug 2, 2024
Ionis downgraded to Market Perform from Outperform at BMO Capital
TheFly
Mani Foroohar
Leerink Partners
62 USD
Upside 81%
3 months ago
Jul 24, 2024
Leerink Partners Upgrades Ionis Pharmaceuticals (IONS) to Outperform
StreetInsider
Akash Tewari
Jefferies
77 USD
Upside 125%
4 months ago
Jul 22, 2024
Ionis Pharmaceuticals (IONS) PT Raised to $77 at Jefferies
StreetInsider
Salveen Richter
Goldman Sachs
33 USD
Downside 4%
4 months ago
Jul 22, 2024
Goldman Sachs Reiterates Sell Rating on Ionis Pharmaceuticals (IONS)
StreetInsider
Akash Tewari
Jefferies
75 USD
Upside 119%
4 months ago
Jul 16, 2024
Jefferies Double Upgrades Ionis Pharmaceuticals (IONS) to Buy
StreetInsider
Paul Matteis
Stifel Nicolaus
53 USD
Upside 55%
4 months ago
Jun 27, 2024
Ionis Pharmaceuticals price target raised to $53 from $50 at Stifel
TheFly
Luca Issi
RBC Capital
70 USD
Upside 104%
5 months ago
Jun 17, 2024
RBC Capital Reiterates Outperform Rating on Ionis Pharmaceuticals (IONS)
StreetInsider
William Pickering
Tudor Pickering
44 USD
Upside 28%
5 months ago
Jun 14, 2024
Bernstein SocGen Group Upgrades Ionis Pharmaceuticals (IONS) to Market Perform
StreetInsider
Kostas Biliouris
BMO Capital
67 USD
Upside 95%
6 months ago
May 17, 2024
BMO Capital Reiterates Outperform Rating on Ionis Pharmaceuticals (IONS)
StreetInsider
Unknown Analyst
Leerink Partners
34 USD
Downside 1%
1 year ago
Feb 3, 2023
SVB Leerink Maintains Market Perform on Ionis Pharmaceuticals, Raises Price Target to $34
Benzinga
Show More Price Targets
Show Less Price Targets
Debjit Chattopadhyay
Guggenheim
Price Target 65 USD
Upside/Downside 90%
View Source
Kostas Biliouris
BMO Capital
Price Target 60 USD
Upside/Downside 75%
View Source
Mani Foroohar
Leerink Partners
Price Target 62 USD
Upside/Downside 81%
View Source
Akash Tewari
Jefferies
Price Target 77 USD
Upside/Downside 125%
View Source
Salveen Richter
Goldman Sachs
Price Target 33 USD
Upside/Downside 4%
View Source
Akash Tewari
Jefferies
Price Target 75 USD
Upside/Downside 119%
View Source
Paul Matteis
Stifel Nicolaus
Price Target 53 USD
Upside/Downside 55%
View Source
Luca Issi
RBC Capital
Price Target 70 USD
Upside/Downside 104%
View Source
William Pickering
Tudor Pickering
Price Target 44 USD
Upside/Downside 28%
View Source
Kostas Biliouris
BMO Capital
Price Target 67 USD
Upside/Downside 95%
View Source
Unknown Analyst
Leerink Partners
Price Target 34 USD
Upside/Downside 1%
View Source
Show More Price Targets
Show Less Price Targets
Ionis Pharmaceuticals Inc Competitors:
Price Targets
SVE
Synthaverse SA
52% Upside
NVAX
Novavax Inc
106% Upside
PYC
PYC Therapeutics Ltd
77% Upside
LVTX
LAVA Therapeutics NV
368% Upside
XNCR
Xencor Inc
44% Upside
PTGX
Protagonist Therapeutics Inc
23% Upside
301301
Yili Chuanning Biotechnology Co Ltd
17% Downside
CANTA
Cantargia AB
389% Upside

Revenue
Forecast

Revenue Estimate
Ionis Pharmaceuticals Inc

For the last 8 years the compound annual growth rate for Ionis Pharmaceuticals Inc's revenue is 14%. The projected CAGR for the next 3 years is 7%.

14%
Past Growth
7%
Estimated Growth
Estimates Accuracy
7%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Ionis Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-9%
Average Miss

Net Income
Forecast

Net Income Estimate
Ionis Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-31%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is IONS's stock price target?
Price Target
61.92 USD

According to Wall Street analysts, the average 1-year price target for IONS is 61.92 USD with a low forecast of 37.37 USD and a high forecast of 80.85 USD.

What is Ionis Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
7%

For the last 8 years the compound annual growth rate for Ionis Pharmaceuticals Inc's revenue is 14%. The projected CAGR for the next 3 years is 7%.

Back to Top